Kura Oncology (KURA) said Monday the first patients have been dosed in phase 1 trial of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors after imatinib failure.
The combination showed robust and durable antitumor activity in preclinical models, the company said.
After completion of the dose-escalation portion of the trial, Kura said it plans expansion cohorts to further assess the safety, tolerability, and clinical activity of ziftomenib.
Price: 6.45, Change: +0.02, Percent Change: +0.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.